|
|
|
|
 Dr Patrick Matthias,
Senior Group Leader Friedrich Miescher Institute for Biomedical Research (Part of the Novartis Research Foundation) Patrick Matthias, PhD, has a long interest in the regulation of gene expression, in particular in the lymphoid system. He studied biology at the University of Geneva and then went to the German Cancer Research Center for his PhD which he received from the University of Heidelberg. He subsequently did postdoctoral studies at the University of Zürich and at the Whitehead Institute of MIT (Cambridge, USA), where he worked with Nobel Laureate Prof. David Baltimore. Patrick Matthias then joined the Friedrich Miescher Institute for Biomedical Research in Basel, Switzerland where he currently is a Senior Group Leader; he is also an Adjunct Professor at the University of Basel. The Matthias laboratory has long been interested in studying the transcriptional control of B cell development. During the last years a central focus of research has also been the study of histone deacetylases (HDACs), enzymes that regulate chromatin acetylation and control gene expression. Numerous studies have shown that HDACs inhibition is beneficial in diverse pathologic settings and this has lent strong support to the concept of therapeutic targeting of epigenetic mechanisms. Work in the laboratory of Patrick Matthias has contributed importantly to understanding the role of specific HDACs, in particular HDAC1, 2 and 6, in normal and in pathological situations.
Patrick Matthias is a member of the Faculty of 1000 and serves on several editorial and review boards. He is also the President of the Forum for Genetic Research, an organ of the Swiss Academy of Natural Sciences which fosters an interdisciplinary dialogue with political bodies and lay people on the impact of gene technology in our society.
Appearing: DAY 2 WEDNESDAY 22 SEPTEMBER – IMPROVING PRE-CLINICAL & EARLY DEVELOPMENT 2.10pm Targeting cancer by epigenetic therapies: example from HDAC inhibitors
- Core concepts to consider when approaching targeted therapy for cancer from an epigenetics perspective.
- Understanding the challenges involved in epigenetic target discovery and validation, and subsequent drug discovery.
- Update on clinical data, future outlook and opportunities.
Dr Patrick Matthias, Senior Group Leader,
Friedrich Miescher Institute for Biomedical Research (Part of the Novartis Research Foundation) 4.40pm Expert Q&A panel discussion: are we aiming at a moving target?
- Different approaches to targeted therapy: is the target actually the driving force?
- What are the implications for therapies which have an effect in patients without a particular target? Does this interrupt that targeted cancer therapy paradigm?
- Understanding strategies and solutions to improve targets for cancer therapy.
Senior Vice President Oncology,
Merck Serono Head of Experimental Oncology Department,
Institute de Recherche Pierre Fabre Chief Technology Officer,
Silicon Biosystems Dr Patrick Matthias, Senior Group Leader,
Friedrich Miescher Institute for Biomedical Research (Part of the Novartis Research Foundation) |
|
|
|
|
Conference:
Day 1
September 21, 8:30am - 5:30pm
Day 2
September 22, 8:30am - 5:30pm
Day 3
September 23, 9am - 5:30pm
|
|
|
|
|
|
|
|
|
